Metformin for non-small cell lung cancer patients: opportunities and pitfalls
Despite exciting advances of the anticancer armamentarium in the recent years, mortality of non-small cell lung cancer (NSCLC) remains high and novel treatments are requisite. Therapy intensification is explored with promising, but expensive and potentially toxic new compounds. Repositioning already existing drugs for cancer treatment could save money and improve patient outcomes in specific contexts. Observational data suggest that use of the standard antidiabetic agent metformin decreases lung cancer incidence and mortality.
Source: Critical Reviews in Oncology Hematology - Category: Cancer & Oncology Authors: Antonin Levy, J érôme Doyen Source Type: research
More News: Cancer | Cancer & Oncology | Fortamet | Hematology | Lung Cancer | Metformin | Non-Small Cell Lung Cancer | Toxicology